FANCB and ovarian cancer: In the present study, we verified that a l-BSO@PUREG4-FA2 nanoformulation (Figure 7) is more effective in inducing ovarian cancer cells death than free l-BSO; and that ovarian cancer cells are more sensitive to l-BSO@PUREG4-FA2 than non-cancer squamous cells (HaCaT), reinforcing a putative therapy mediated by abdominal infusion.